EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization, and Costs in Advanced Hepatocellular Carcinoma in Ontario, Canada

Soo Jin Seung, Hasnain Saherawala, YongJin Kim, Jimmy Tieu, Sharon Wang, Cal Shephard, Dominick Bossé iD

Cancers · 15.06.2024 · 16 (12) · 2232

DOI: 10.3390/cancers16122232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 15.06.2024. Verfasst von Soo Jin Seung und 6 weiteren Autor:innen. Beteiligte Einrichtung: HOPE Research Centre, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic landscape for aHCC has evolved in recent years, necessitating a comprehensive analysis of treatment patterns, clinical outcomes, HCRU, and costs to contextualize emerging treatments. This study aimed to investigate these outcomes using real-world data from Ontario, Canada. This retrospective cohort study was conducted using linked administrative databases from April 2010 to March 2020. Patients diagnosed with aHCC were included, and their clinical and demographic characteristics were analyzed, as well as treatment patterns, survival, HCRU, and economic burden. Among 7322 identified patients, 802 aHCC patients met the eligibility criteria for inclusion in the study. Treatment subgroups included 1L systemic therapy (53.2%), other systemic treatments (4.5%), LRT (9.0%), and no treatment (33.3%). The median age was 66 years, and the majority were male (82%). The mOS for the entire cohort from diagnosis was 6.5 months. However, patients who received 1L systemic therapy had an mOS of 9.0 months, which was significantly higher than the other three subgroups. The mean cost per aHCC-treated patient was $49,640 CAD, with oral medications and inpatient hospitalizations as the largest cost drivers. The results underscore the need for the continuous evaluation and optimization of HCC management strategies in the era of evolving therapeutic options.

Schlagwörter

Stichwörter der Autor:innen

CanadaHCCadministrative dataadvanced hepatocellular carcinomacostingreal-world evidenceresource utilizationsurvival

Autor:innen und Institutionen

  • HOPE Research Centre, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.
  • AstraZeneca Canada, 1004 Middlegate Road, Mississauga, ON L4Y 1M4, Canada.
  • Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.

ORCID-Profile: Dominick Bossé

Förderung

  • AstraZeneca Canada

Zitieren

APA

Seung, S. J., Saherawala, H., Kim, Y., Tieu, J., Wang, S., Shephard, C., & Bossé, D. (2024). Real-World Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization, and Costs in Advanced Hepatocellular Carcinoma in Ontario, Canada. Cancers, 16(12), 2232. https://doi.org/10.3390/cancers16122232

Vancouver

Seung SJ, Saherawala H, Kim Y, Tieu J, Wang S, Shephard C, et al. Real-World Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization, and Costs in Advanced Hepatocellular Carcinoma in Ontario, Canada. Cancers. 2024;16(12):2232. doi:10.3390/cancers16122232

BibTeX
@article{Seung2024,
  author = {Seung, Soo Jin and Saherawala, Hasnain and Kim, YongJin and Tieu, Jimmy and Wang, Sharon and Shephard, Cal and Bossé, Dominick},
  title = {Real-World Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization, and Costs in Advanced Hepatocellular Carcinoma in Ontario, Canada},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {12},
  pages = {2232},
  doi = {10.3390/cancers16122232}
}
Kostenlos starten →